Loading...
Nonalcoholic fatty liver disease (NAFLD) is a common cause of liver disease but has no specific pharmacologic remedies. Now, investigators have tested the efficacy of aramchol, a novel synthetic lipid molecule that has reduced hepatic fat content in animals on a high-fat diet.
In a double-blind, multicenter trial conducted in Israel, 60 patients with biopsy-proven NAFLD were randomized to receive 100 mg or 300 mg of aramchol or placebo daily for 3 months. The primary endpoint was the change in hepatic fat content based on magnetic resonance spectroscopy. Secondary endpoints included changes in liver enzymes, homeostasis model assessment scores, and levels of adiponectin.
Between baseline and 3 months, hepatic fat content increased in the plac…